MedTrace Logo

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

NCT01208233 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2016-02-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.

Conditions

Interventions

DRUG

PF-03049423

1 mg of PF-03049423 daily for 90 days

DRUG

PF-03049423

3 mg of PF-03049423 daily for 90 days

DRUG

PF-03049423

6 mg of PF-03049423 daily for 90 days

OTHER

Placebo

Placebo of PF-03049423 daily for 90 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Germany
  • Hungary
  • India
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01208233 on ClinicalTrials.gov